Close
4

Seqens Seqens

X

Company profile for MinervaX

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
MinervaX announces completion of 47.4 mEUR financing with Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joining existing investors Novo Holding's REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment. Proceeds will be used to advance the Company's GBS vaccine through Phase II and preparation for Phase III. Minervax ApS is a biotechnology company based out of 28 Vedbendvej, Hellerup, C...
MinervaX announces completion of 47.4 mEUR financing with Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joining existing investors Novo Holding's REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment. Proceeds will be used to advance the Company's GBS vaccine through Phase II and preparation for Phase III. Minervax ApS is a biotechnology company based out of 28 Vedbendvej, Hellerup, Capital Region of Denmark, Denmark. MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci.The National Institute of Health of the US has identified prevention of GBS in newborns.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
MinervaX
Denmark Flag
Country
Country
Denmark
Address
Address
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY